Literature DB >> 10720419

Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart.

H Nakajima1, H O Nakajima, O Salcher, A S Dittiè, K Dembowsky, S Jing, L J Field.   

Abstract

Increased transforming growth factor (TGF)-beta(1) activity has been observed during pathologic cardiac remodeling in a variety of animal models. In an effort to establish a causal role of TGF-beta(1) in this process, transgenic mice with elevated levels of active myocardial TGF-beta(1) were generated. The cardiac-restricted alpha-myosin heavy chain promoter was used to target expression of a mutant TGF-beta(1) cDNA harboring a cysteine-to-serine substitution at amino acid residue 33. This alteration blocks covalent tethering of the TGF-beta(1) latent complex to the extracellular matrix, thereby rendering a large proportion (>60%) of the transgene-encoded TGF-beta(1) constitutively active. Although similar levels of active TGF-beta(1) were present in the transgenic atria and ventricles, overt fibrosis was observed only in the atria. Surprisingly, increased active TGF-beta(1) levels inhibited ventricular fibroblast DNA synthesis in uninjured hearts and delayed wound healing after myocardial injury. These data suggest that increased TGF-beta(1) activity by itself is insufficient to promote ventricular fibrosis in the adult mouse ventricle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720419     DOI: 10.1161/01.res.86.5.571

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  90 in total

Review 1.  Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia.

Authors:  Razi Khan; Richard Sheppard
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

Review 2.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

3.  Overexpression of bone morphogenetic protein 10 in myocardium disrupts cardiac postnatal hypertrophic growth.

Authors:  Hanying Chen; Weidong Yong; Shuxun Ren; Weihua Shen; Yongzheng He; Karen A Cox; Wuqiang Zhu; Wei Li; Mark Soonpaa; R Mark Payne; Diego Franco; Loren J Field; Vicki Rosen; Yibin Wang; Weinian Shou
Journal:  J Biol Chem       Date:  2006-06-23       Impact factor: 5.157

4.  Angiotensin type 1 (AT1) and type 2 (AT2) receptors mediate the increase in TGF-beta1 in thyroid hormone-induced cardiac hypertrophy.

Authors:  G P Diniz; M S Carneiro-Ramos; M L M Barreto-Chaves
Journal:  Pflugers Arch       Date:  2007-01-06       Impact factor: 3.657

5.  Qiliqiangxin attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in rabbits.

Authors:  Hou Tingting; Liu Guangzhong; Zang Yanxiang; Yu DongDong; Sun Li; Weimin Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-09       Impact factor: 3.000

6.  Cardiomyocyte cell cycle activation ameliorates fibrosis in the atrium.

Authors:  Hidehiro Nakajima; Hisako O Nakajima; Klaus Dembowsky; Kishore B S Pasumarthi; Loren J Field
Journal:  Circ Res       Date:  2005-11-23       Impact factor: 17.367

Review 7.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

8.  Age-related atrial fibrosis.

Authors:  Felix Gramley; Johann Lorenzen; Christian Knackstedt; Obaida R Rana; Erol Saygili; Dirk Frechen; Sven Stanzel; Francesco Pezzella; Eva Koellensperger; Christian Weiss; Thomas Münzel; Patrick Schauerte
Journal:  Age (Dordr)       Date:  2008-10-07

Review 9.  Intramyocardial fibroblast myocyte communication.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

10.  Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.

Authors:  Dolkun Rahmutula; Gregory M Marcus; Emily E Wilson; Chun-Hua Ding; Yuanyuan Xiao; Agnes C Paquet; Rebecca Barbeau; Andrea J Barczak; David J Erle; Jeffrey E Olgin
Journal:  Cardiovasc Res       Date:  2013-04-23       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.